Leukemia Research
Volume 26, Issue 11 , Pages 1011-1016, November 2002

The kinase inhibitor STI571 reverses the Bcr–Abl induced point mutation frequencies observed in pre-leukemic P190Bcr–Abl transgenic mice

Molecular Oncology Group, Division of Hematology, Department of Medicine, C6 Royal Victoria Hospital, McGill University, 687 Pine Avenue West, Montreal, Que., Canada H3A 1A1

Received 22 May 2001; accepted 22 October 2001.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0145-2126(01)00181-3

Leukemia Research
Volume 26, Issue 11 , Pages 1011-1016, November 2002

Article Tools

* Image Usage & Resolution